Photo: NYU Langone Staff
A new targeted therapy called Tabrecta has been shown to slow or stop the growth of cancer cells in people with metastatic non-small cell lung cancer (NSCLC). Salman R. Punekar, MD, a medical oncologist at NYU Langone Health’s Perlmutter 鶹Ƶapp Center, tells SurvivorNet that while anyone can get lung cancer, current and former smokers are most at risk for NSCLC, which accounts for 84 percent of all lung cancers.
“It’s important to know all that you can about your diagnosis so you’ll be able to make informed decisions about your treatment,” says Dr. Punekar says, also an assistant professor in the at NYU Grossman School of Medicine. “Once you have this information, you and your doctor can come up with a personalized treatment plan that best fits your illness.”
Read more from .
